A Journey into ADC Innovation

A Journey into ADC Innovation

After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more

In-Depth Analysis of ADCs: Part Two

In-Depth Analysis of ADCs: Part Two

Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more

Technical Insights into 15 ADC Drugs and Future Innovations

Technical Insights into 15 ADC Drugs and Future Innovations

GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more

Understanding DAC Design Points and Representative Cases in PROTAC

Understanding DAC Design Points and Representative Cases in PROTAC

Protein Hydrolysis Targeted Chimeras (PROTAC) are bringing revolutionary changes to the fields of biology and medicinal chemistry. PROTAC consists of a target protein ligand, an E3 ligase ligand, and a spacer group[Unlike the linker used in antibody-drug conjugates, here we specifically use “spacer” instead of the commonly seen “linker” in PROTAC literature]. PROTAC structural composition … Read more

Comparative Analysis of SMDC, ADC, and DAC in Cancer Treatment

Comparative Analysis of SMDC, ADC, and DAC in Cancer Treatment

To deliver chemotherapy drugs more effectively, small molecule drug conjugates (SMDC), antibody-drug conjugates (ADC), and degrader-antibody conjugates (DAC) have been explored and developed, providing selective delivery while improving the therapeutic index. What are their similarities and differences? What are their respective advantages? What is the current state of research? What does the future hold? This … Read more

A Comprehensive Guide to Non-Clinical Pharmacology and Toxicology Assessment of ADCs

A Comprehensive Guide to Non-Clinical Pharmacology and Toxicology Assessment of ADCs

Recently, ADC (Antibody-Drug Conjugate) conferences have been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main venue for ADCs. Developing an entry-level ADC seems not difficult, but evaluating the pharmacology and toxicology in the preclinical stage has become a top … Read more

Introduction to ADC: A Brief Overview of Clinical Pharmacology

Introduction to ADC: A Brief Overview of Clinical Pharmacology

Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more

Comprehensive Overview of Antibody-Drug Conjugates (ADCs)

Comprehensive Overview of Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug payload … Read more

Comprehensive Overview of Antibody-Drug Conjugates (ADCs)

Comprehensive Overview of Antibody-Drug Conjugates (ADCs)

Introduction Antibody-drug conjugates (ADC) combine the high specificity of monoclonal antibodies with the high potency of small molecule cytotoxic drugs to enhance the targeting of cancer therapies and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs can release highly active cytotoxins within tumor tissues, theoretically leading to higher efficacy. ADCs have undergone … Read more

Mechanisms of ADC Toxicity and Strategies to Enhance Tolerability

Mechanisms of ADC Toxicity and Strategies to Enhance Tolerability

Key Content Preview:In recent years, antibody-drug conjugates (ADCs) have developed rapidly. As of August 2023, there are a total of 15 ADCs on the market globally, with over 1200 drugs under research. In June this year, Nature Biotechnology published a brief report titled “ADCs’ Revival”, highlighting the “breakthrough momentum” of ADCs in new drug development. … Read more